A Study to Investigate Safety and Effectiveness of Pancreatic Cells Derived from Pigs (OPF-310) in Patients with Type 1 Diabetes Mellitus

Recruiting

Phase 1

Phase 2

A Study to Investigate Safety and Effectiveness of Pancreatic Cells Derived from Pigs (OPF-310) in Patients with Type 1 Diabetes MellitusA Study to Investigate Safety and Effectiveness of Pancreatic Cells Derived from Pigs (OPF-310) in Patients with Type 1 Diabetes Mellitus

Sponsor:

Otsuka Pharmaceutical Factory, Inc.

Code:

NCT06575426

Conditions

Diabetes Mellitus, Type 1

Hypoglycemia

Eligibility Criteria

Sex: All

Age: 35 - 65

Healthy Volunteers: Not accepted

Interventions

OPF-310

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Otsuka Pharmaceutical Factory, Inc. on 2025-03-25.